Abstract Number: 0498 • ACR Convergence 2023
Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE)
Background/Purpose: Major adverse cardiovascular events (MACE) are known comorbidities and consequences of psoriasis (PsO) and psoriasis arthritis (PsA). Previous studies underlined the potential of immunomodulatory…Abstract Number: 0746 • ACR Convergence 2023
The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis
Background/Purpose: Ultrasound (US) may improve characterization of psoriatic arthritis (PsA) phenotypes and help predict disease outcomes. We aimed to assess whether US phenotypes are associated…Abstract Number: 1210 • ACR Convergence 2023
Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis
Background/Purpose: Data suggest that patient satisfaction with drug therapy in psoriasis (Pso) and psoriatic arthritis (PsA) is associated with treatment compliance and, ultimately, disease response.…Abstract Number: 1421 • ACR Convergence 2023
Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS)
Background/Purpose: Sustained minimal disease activity (MDA) is achieved by a minority of patients (pts) receiving biologics for psoriatic arthritis (PsA). Pt-reported MDA domains are less…Abstract Number: 1437 • ACR Convergence 2023
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study
Background/Purpose: Given the chronic nature of PsA, sustaining high levels of disease control with treatment is important. Assessing maintenance of response in patients (pts) that…Abstract Number: 1691 • ACR Convergence 2023
16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast
Background/Purpose: Oligoarticular PsA can be associated with significant impact on quality of life, despite limited joint involvement. The phase 4 FOREMOST study evaluated the efficacy…Abstract Number: 2227 • ACR Convergence 2023
The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration
Background/Purpose: Smoking has been associated with higher disease activity, poorer treatment response, and drug retention rate among psoriatic arthritis (PsA) patients treated with Tumor Necrosis…Abstract Number: 2243 • ACR Convergence 2023
Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis
Background/Purpose: Enthesitis is a key clinical and imaging hallmark in psoriatic arthritis (PsA). ULTIMATE (NCT02662985) demonstrated responsiveness of ultrasound (US) detected synovitis and enthesitis in…Abstract Number: 2538 • ACR Convergence 2023
Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study
Background/Purpose: Psoriasis and type 2 diabetes mellitus (T2D) may share common underlying pathophysiology, in which the pathogenesis of psoriasis is mediated by NOD-like receptor family…Abstract Number: 0483 • ACR Convergence 2023
The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)
Background/Purpose: Co-morbid fibromyalgia has been shown to be an important influence on non-response in patients with some inflammatory arthritides. Around 1 in 5 patients with…Abstract Number: 0499 • ACR Convergence 2023
Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
Background/Purpose: Improvement in both joint and skin manifestations is an important goal in the treatment of psoriatic arthritis (PsA). This study describes durability of 50%…Abstract Number: 0750 • ACR Convergence 2023
Multispectral Optoacoustic Tomography of the Entheses Reveals Common Metabolic and Architectural Tissue Patterns in Psoriasis and Psoriatic Arthritis Independent of Inflammation
Background/Purpose: Multispectral optoacoustic tomography (MSOT) is a novel imaging platform that combines ultrasound (US) with optoacoustic imaging to allow non-invasive in vivo quantification of key…Abstract Number: 1217 • ACR Convergence 2023
Sex Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey
Background/Purpose: Women with PsA have more severe disease activity and lower health-related quality of life vs men.1 This post hoc analysis assessed sex differences in…Abstract Number: 1422 • ACR Convergence 2023
Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
Background/Purpose: Risankizumab, an interleukin-23 inhibitor, was efficacious and well tolerated in plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinical trials.The objective of this integrated data…Abstract Number: 1438 • ACR Convergence 2023
Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA
Background/Purpose: Late-onset PsA may be associated with elevated acute phase reactants, higher joint count, and erosive disease at diagnosis1,2. Given potential phenotype differences and increasing…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 93
- Next Page »